IGA Nephropathy Disease Treatment Market Forecasts from 2023 to 2028

The IgA Nephropathy disease treatment market is projected to grow at a CAGR of 18.47% during the forecast period reaching US$469.283 million by 2028, from US$143.274 million in 2021.

The need for IgA nephropathy disease treatment is estimated to shoot up in the coming years on account of the increasing prevalence of kidney diseases. For instance, according to the National Institute of Diabetes and Digestive and Kidney Disease, in 2020, 786, 000 Americans were diagnosed with end-stage kidney disease with 71% of them being on dialysis and 29% having a kidney transplant. The research is going on to find new and effective treatment methods and will continue providing growth opportunities for the key market players during the forecast period.

Growth Drivers of the IgA Nephropathy disease treatment Market

Clearances and approval of new drugs, as well as major campaigns establishments for increasing awareness among people regarding IgA Nephropathy disease and health checkups, will have a positive impact on the market growth. For instance, US Food and Drug Administration, in September 2022, provided clearance to the Investigational New Drug (IND) Application of Eldon Pharmaceutical for assessment of tegoprubart to treat IgA Nephropathy.

Research and Developments Related to IgA Nephropathy

The number of people being affected with rare diseases such as IgA Nephropathy is increasing because most of the population is following a sedentary lifestyle and have poor food habits. Moreover, in underdeveloped regions, the low-income population does not practice proper hygiene and does not get essential nutrients and vitamins to keep the body healthy. The rising per capita income in developing regions is augmenting the need for quality healthcare services and disease treatment.

Hence, to cater to such growing needs major various governing authorities and major companies are undertaking various strategies relating to launches, innovation, and development of new drugs and treatments. For instance, the US Food and Drug Administration, in December 2021, approved the Tarpeyo drug to reduce proteinuria in adults who are having primary IgA Nephropathy.

The therapy segment of the IgA nephropathy disease treatment market is anticipated to grow.

The rapid development of therapies and new investments are accelerating the adoption of these treatment methods by healthcare professionals. As per the Q3 2021 Gene, Cell & RNA Therapy Landscape Report by ASGCT, 2 RNA therapies in the clinical stage are being developed for Berger’s disease among the non-oncology rare diseases.

In addition, clinical developments, and trials of gene therapies for IgA nephropathy diseases are expected to boost this treatment method. For instance, according to the National Library of Medicine in March 2022, nanoparticle and adeno-associated viral vector technologies offer emerging hope for kidney gene therapy. Furthermore, according to the Q2 2022 Quarterly Data Report by the American Society of Gene & Cell Therapy (ASGCT), 3 RNA gene therapies each are in pipeline development for over 12 rare diseases including Berger’s disease.

The United States in North America is an Expected Dominant Market

Growing health consciousness coupled with high per capita disposable income is significantly contributing to the market growth. According to a nationwide study published in the Journal of the American Society of Nephrology, the incidence rate of IgA nephropathy (IgAN) is estimated to be 2-10 per 100, 000 individuals a year.

The USA is at high risk for such diseases due to the growing number of chronic diseases and a sedentary lifestyle. According to the US National Institute of Diabetes and Digestive and Kidney Disease, Department of Health and Human Services, Chronic kidney disease (CKD) affects more than one in seven US Adults. As per the report by the Centers for Disease Control and Prevention (CDC) on chronic kidney disease in the United States, in 2021, there are about 37 million people affected by chronic kidney diseases.

Key Developments

• In May 2022, Calliditas launched its educational program on IgA Nephropathy called “IgAN Connect” which will provide necessary tools and sources to people who are either recently been diagnosed with IgA Nephropathy or are living for many years. Such drug approval and clearances coupled with education programs relating to IgA Nephropathy present a positive outlook for the IgA Nephropathy market over the coming years.
• In September 2022, STADA launched a unique drug in the German market for the treatment of the rare kidney disease IgA Nephropathy. The drug will come in capsules and will be available for primary patients of IgA Nephropathy and will be exclusively marketed in the European Economic Area (EEA) by the company.
• In June 2021, Novartis announced the Phase II study of its investigational product iptaocpan which aims to reduce proteinuria thereby stabilizing the kidney functioning of the patients.
• In August 2022, Bayer rolled out a new product namely “kerendia” which is an oral drug for the treatment of people suffering from chronic kidney diseases such as IgA Nephropathy. Such rapid innovations, and approval of new drugs for the treatment of IgA Nephropathy coupled with the growing prevalence of kidney disease, are expected to accelerate the development and marketing of drugs and treatment methods.

Segmentation:

By Test

• Blood Test
• Urine Test
• Kidney Test
• Iotholamate Clearance Test
• Others

By Treatment Type

• Corticosteroids
• Immunosuppressive drugs
• ACB Inhibitors and ARBs
• Diet Change
• Therapy

By Geography

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• Japan
• China
• India
• South Korea
• Indonesia
• Thailand
• Others